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The present study explored the potential causal link between ischemia-driven cyclooxygenase-2 (COX-2) expression and enhanced
apoptosis duringmyocardial ischemia/reperfusion (I/R) by using H9C2 cardiomyocytes and primary rat cardiomyocytes subjected
to hypoxia/reoxygenation (H/R). The results showed that H/R resulted in higher COX-2 expression than that of controls, which
was prevented by pretreatment with Helenalin (NF𝜅B specific inhibitor). Furthermore, pretreatment with NS398 (COX-2 specific
inhibitor) significantly attenuatedH/R-induced cell injury [lower lactate dehydrogenase (LDH) leakage and enhanced cell viability]
and apoptosis (higher Bcl2 expression and lower level of cleaved caspases-3 and TUNEL-positive cells) in cardiomyocytes.
The amelioration of posthypoxic apoptotic cell death was paralleled by significant attenuation of H/R-induced increases in
proinflammatory cytokines [interleukin 6 (IL6) and tumor necrosis factor (TNF𝛼)] and reactive oxygen species (ROS) production
and by higher protein expression of phosphorylated Akt and inducible nitric oxide synthase (iNOS) and enhanced nitric oxide
production. Moreover, the application of LY294002 (Akt-specific inhibitor) or 1400W (iNOS-selective inhibitor) cancelled the
cellular protective effects of NS398. Findings from the current study suggest that activation of NF𝜅B during cardiomyocyte H/R
induces the expression of COX-2 and that higher COX-2 expression during H/R exacerbates cardiomyocyte H/R injury via
mechanisms that involve cross talks among inflammation, ROS, and Akt/iNOS/NO signaling.
1. Introduction
Ischemic heart disease caused by partial or complete blockage
of coronary arteries is a leading cause for morbidity andmor-
tality worldwide, especially in developed countries/regions
[1]. It is well known that the most effective intervention to
reduce myocardial ischemic injury is restoration of the coro-
nary blood flow. Clinically, restoration of the coronary blood
flow improved the survival rate of the patient in general, but
the process of myocardial reperfusion itself may also induce
additional cardiac damage and complications, referred to
as “myocardial ischemia/reperfusion (I/R) injury” [1, 2].
Although the molecular mechanisms mediating reperfusion
injury are largely unknown, the underlying pathophysiology
of myocardial I/R injury likely involves many factors, such
as reactive oxygen species (ROS) formation, activation of cell
apoptosis, and inflammatory responses [2, 3].
Cyclooxygenase- (COX-) 1 and COX-2 are the two iso-
forms of cyclooxygenase, both of which catalyze the trans-
formation of arachidonic acid to prostanoids [4–6]. COX-
1 is widely and constitutively distributed in the body while
COX-2 is expressed at low levels and is strongly induced
in response to different stimuli [7]. Accumulating evidence
has proved that COX-2 is highly expressed in the cardiac
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tissue during myocardial ischemia, suggesting that induction
of COX-2 may be involved in ischemic heart disease [8, 9].
Although COX-2 expression after ischemic preconditioning
in animal models of myocardial I/R has been considered
to be cardioprotective [10, 11], more reports have suggested
that enhancement of COX-2 expression plays a detrimental
role in the development of myocardial I/R injury [12–15]. In
particular, treatment with a COX-2 specific inhibitor signif-
icantly improved cardiac function and reduced infarct size
after myocardial infarction in different experiment animal
models, including rat [12, 13, 16], rabbit [14], and dog [15].
However, it has not been explored how inhibition of COX-2
protects against cardiac damage duringmyocardial I/R injury.
Necrosis and apoptosis have been considered as major
morphologically distinct pathways that regulate tissue dam-
age [17]. For a long time necrosis was believed to be the
exclusive cause of cell death during myocardial I/R injury.
More recent studies have demonstrated that cardiomyocyte
apoptosis also contributes to the process of cardiac dam-
age during I/R injury, which causes the loss of cardiomy-
ocyte volume and the subsequent cardiac dysfunction [18,
19]. Therefore, exploring ways to control or attenuate I/R-
induced increase in cardiomyocytes apoptosis is of clinical
interest for improving postischemic recovery. A previous
study reported that the presence and the content of COX-
2 were positively correlated with the severity of apoptosis
at the site of acute myocardial infarction [20]. However,
whether there is a causal link between ischemia-driven COX-
2 expression and apoptosis during I/R injury and in particular
the impact of ischemia-induced increases in COX-2 on
conventional cardiac prosurvival signaling molecules such as
Akt and nitric oxide (NO) [21–23] have not been explored.
Thus, the present study investigated the molecular basis of
potential cause-effect link between COX-2 expression and
apoptosis during ischemia using rat origin cardiomyocytes
(H9C2) and primary adult rat cardiomyocytes subjected to
hypoxia/reoxygenation (H/R).
2. Materials and Methods
2.1. H9C2 Cells Culture and Isolation of Primary Adult
Rat Cardiomyocyte. The rat cardiomyocyte-derived cell line
H9C2 was purchased from the American Type Culture
Collection (ATCC, Manassas, VA, USA). H9C2 cells from
passage 5 to passage 20 were used in this study. These
cells were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM, Cat. number 11185-084, ThermoFisher Scientific,
Waltham, MA, USA) supplemented with 10% fetal bovine
serum (FBS, Cat. number FB-1001/500, Biosera, Kansas City,
MO, USA) and 1% penicillin/streptomycin (100U/mL, Cat.
number 15140122, ThermoFisher Scientific). Primary adult
rat cardiomyocytes were isolated as described [24]. Briefly,
hearts from male Sprague-Dawley rat (8 to 10 weeks of age)
were rapidly removed and retrogradely perfused at 37∘C
for 20min by perfusate including collagenase II (2mg/mL,
Cat. number 17101-015, ThermoFisher Scientific) and CaCl
2
(50𝜇M). Subsequently the heart was quickly removed and
gently teased into small pieces, and the dispersed myocytes
were then filtered through 70 𝜇m nylon cell strainer. The
cardiomyocytes were resuspended with M199 medium (Cat.
number 11150-059, ThermoFisher Scientific) supplemented
with 10%FBS and 1% insulin/transferring/selenium (ITS, Cat.
number 13146, Sigma-Aldrich, St. Louis, MO, USA) in 6-well
plates precoatedwithMatrigel (Cat. number 354248, Corning
Life Sciences, Corning, NY, USA). All cells were incubated
at 37∘C in a room air atmosphere containing 5% CO
2
-95%
O
2
.
2.2. Cell Treatment. The rat cardiomyocytes were randomly
divided into three groups: (1) control (CTL) group: the cells
were incubated in DMEM medium (5.5mM glucose, H9C2
cells) or M199 medium (primary rat cardiomyocytes), (2)
hypoxia/reoxygenation (H/R) group: since the H9C2 car-
diomyocytes and primary adult rat cardiomyocytes showed
different sensitivity to the hypoxia and reoxygenation treat-
ment (unpublished observations), then these two kinds of
cells were incubated in DMEM medium with no glucose or
serum with different duration of time [6 hours (h) (H9C2
cells) or 45 minutes (min) (primary rat cardiomyocytes) for
hypoxia and 12 h (H9C2 cells) or 2 h (primary rat cardiomy-
ocytes) for reoxygenation]. Hypoxia was achieved by placing
the cells on a humidified Plexiglas chamber, containing 95%
N
2
and 5% CO
2
to mimic ischemia. Reoxygenation was
achieved by exposing cell to normal medium and room air
with atmosphere containing 5% CO
2
-95% O
2
at 37∘C, and
(3) H/R + Helenalin or H/R + NS398 group: according to
the earlier work in the laboratory or from the literature
[25, 26], the usage of Helenalin (NF𝜅B specific inhibitor, Cat.
number ALX-350-120-MC05, Enzo Life Sciences, Syosset,
NY, USA) and NS398 (COX-2 specific inhibitor, Cat. number
N194, Sigma) at the following concentration and exposure
time exerted significant inhibitory effects on NF𝜅B and
COX-2 activity, respectively. The cells were preincubated
with Helenalin (10𝜇M, 2 h) [25] or NS398 (10 𝜇M, 1 h) [26]
and followed by H/R treatment. Helenalin or NS398 was
added to the changed medium during H/R stimulation to
keep the working concentration. At harvest time, cultured
medium was snap-frozen in liquid N
2
and cells pellets
were homogenized in TRIzol (Invitrogen Life Technologies,
Carlsbad, CA, USA) for RNA extraction or 1x lysis buffer
(Cat. number 9803S, Cell Signaling,USA) supplementedwith
Protease Inhibitor Cocktail (Cat. number P8340, Sigma) for
protein extraction for future analysis.
2.3. Analysis of LDH Leakage and Cell Viability. Cell injury
was evaluated by lactate dehydrogenase (LDH) leakage. The
released LDH in the collected medium was determined by
using a commercial LDH kit (Cat. number 11644793001
Roche, Mannheim, Germany) according to the manufac-
turer’s instructions. The cell viability of the H9C2 cells and
primary adult rat cardiomyocytes was determined by the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay as described [27, 28]. Briefly, cells were seeded
in 96-well plates and were incubated with MTT solution
(1mg/mL, Cat. number M5655, Sigma) at 37 ∘C for 4 h
after the various treatments. The formazan crystals were
dissolved with dimethyl sulfoxide (DMSO, 100mL/well),
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Table 1: Primers used in quantitative real-time polymerase chain reactions.
Gene Forward sequence 5󸀠→3󸀠 Reverse sequence 5󸀠→3󸀠
𝛽-actin AGGCCAACCGTGAAAAGATG ACCAGAGGCATACAGGGACAA
IL1𝛽 TACCTATGTCTTGCCCGTGGA ATCATCCCACGAGTCACAGAGG
IL6 ACTTCACAAGTCGGAGGCTT AGTGCATCATCGCTGTTCAT
TNF𝛼 TCTCAAAACTCGAGTGACAAGC GGTTGTCTTTGAGATCCATGC
IL1𝛽 = interleukin 1𝛽; IL6 = interleukin 6; and TNF𝛼 = tumor necrosis factor 𝛼.
and the absorbance was detected at 570 nm with Epoch
microplate spectrophotometer (BioTek,Winooski, VT,USA).
2.4. Real-Time Polymerase Chain Reaction. Total RNA was
extracted from H9C2 cells using TRIzol. Equal amounts
of RNA were reverse-transcribed and processed using the
PrimeScript RT Master Mix Kit (Cat. number RR036Q,
Takara, Shuzou, Japan), according to the manufacturer’s
instructions. Quantitative real-time PCR was performed as
described [29] using a SYBR Green PCT master mix (Cat.
number RR820A, Takara) on an Applied Biosystems Prism
7000 sequence detection system (Applied Biosystems, Foster
City, CA, USA). The conditions for amplification were 30
seconds at 95∘C for denaturation, 40 cycles of 5 seconds
at 95∘C, and 30 seconds at 60∘C. The gene-specific primers
sequences used were listed in Table 1.ThemRNA levels of the
different genes tested were normalized to those of 𝛽-actin.
2.5. Western Blotting. Total cell lysates were prepared by
lysing primary adult rat cardiomyocytes or H9C2 cells with
1x lysis buffer supplemented with Protease Inhibitor Cocktail.
The protein concentration of the samples was determined
with the Bradford assay (Cat. number 500-0006, Bio-Rad,
Hercules, CA, USA). Equal amounts of protein from each
sample were separated on 8%–12.5% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and transferred onto
PVDFmembranes for detection with appropriate antibodies.
Primary antibodies against COX-2 (1 : 1000, Cat. number
160106) and inducible nitric oxide synthase (iNOS, 1 : 40,
Cat. number ab15323) were purchased from Cayman (Ann
Arbor, MI, USA) and Abcam (Cambridge, MA, USA),
respectively. Primary antibodies against Bcl2-like protein
4 (Bax, 1 : 1000, Cat. number 2772S), Bcl2 (1 : 1000, Cat.
number 2870S), glyceraldehyde 3-phosphate dehydrogenase
(GADPH, 1 : 1000, Cat. number 5174S), inhibitor of kappa
B 𝛼 (I𝜅B𝛼, 1 : 1000, Cat. number 4814S), phospho-I𝜅B𝛼
(1 : 1000, Cat. number 9246S), p65 (1 : 1000, Cat. number
4764S), phospho-p65 (1 : 1000, Cat. number 3033S), total
caspase-3 (1 : 1000, Cat. number 9665S), cleaved caspase-3
(1 : 1000, Cat. number 9661S), total Akt (1 : 1000, Cat. number
9272S), phosphor-Akt (1 : 1000, T450 Cat. number 9267S),
and horseradish peroxidase-conjugated anti-mouse (Cat.
number 7076S) or anti-rabbit (Cat. number 7074S) secondary
antibodies (1 : 3000) were purchased from Cell Signaling
Technology (Danvers, MA, USA). Blots were visualized with
Clarity Western Blotting Detection Reagent (Cat. number
102030726, Bio-Rad) and subsequently exposed to X-ray film
(Carestream, NY, USA). ImageJ software (National Institutes
of Health,MD,USA)was used to analyze the optical densities
of the immunoreactive bands as described [30].
2.6. TUNEL Assay. H9C2 cardiomyocytes were cultured
directly on coverslips. After the treatment, the cardiomy-
ocytes’ apoptosis was determined by TUNEL staining
using an In Situ Cell Death Detection Kit (Cat. number
11684817910, Roche Diagnostics GmbH, Mannheim, Ger-
many), according to the manufacturer’s instructions. Images
were taken using an Olympus BX41 fluorescence microscope
equippedwith anOlympusDP72 color digital camera (Olym-
pus, Tokyo, Japan). Five photos (magnification ×200) were
taken randomly for each sample. Image quantification was
presented as percentage of TUNEL-positive cells among the
total number of cells as described [31].
2.7. Determination of Cyclooxygenase-2 Activity. The COX-
2 activity in H9C2 cell lysates from different groups (CTL,
H/R, and H/R + NS398) was determined by a commercial
COX Fluorescent Activity Assay Kit (Cat. number 700200,
Cayman). The COX-2 activity was detected in the presence
of SC560 (5 𝜇M, COX-1 selective inhibitor) according to the
manufacturer’s instructions.
2.8. Measurement of Intracellular Reactive Oxygen Species and
Nitric Oxide Production. The H9C2 cells were seeded in 96-
well black polystyrene plates (Cat. number 3916, Corning
Life Sciences) at subconfluent level in the presence of NS398
(10 𝜇M for 1 h) or LY294002 (10 𝜇M for 1 h) [32] or 1400W
(1 𝜇M for 30mins) [33] with or without H/R stimulation. To
detect the intracellular level of reactive oxygen species (ROS),
the cells were incubated with dihydroethidium fluorescence
(DHE, 8 𝜇M, Cat. number 37291, Sigma) in a Krebs-HEPES
buffer at 37∘C in dark for 30min. After cells were washed,
fluorescence was measured in a CLARIOstar Monochro-
mator Microplate Reader (BMG LABTECH, Ortenberg,
Germany) by using 518 and 605 nm wavelength excitation
and emission filters, respectively. To detect the intracellu-
lar nitric oxide (NO) production, 4-amino-5-methylamino-
2󸀠,7󸀠-difluorofluorescein diacetate (DAF-FM diacetate, Cat.
number D-23844, ThermoFisher Scientific, Waltham, MA,
US), which becomes fluorescent when it is nitrosylated by
oxidation products of NO, was added to the H9C2 cells in
a working concentration of 10 𝜇M and allowed to incubate at
37∘C in dark for 30min. After cells were washed, fluorescence
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was detected in a CLARIOstar Monochromator Microplate
Reader with 495 nm excitation and 515 nm emission.
2.9. Statistical Analysis. All data are expressed as the means
± SEM. Comparison between two groups was carried out
by two-tailed nonparametric Mann–Whitney U test or one-
way ANOVA followed by Tukey’s test, wherever appropriate,
using the GraphPad Prism 5.0 software (San Diego, CA,
USA). Differences were considered statistically significant
when 𝑃 was less than 0.05.
3. Results
3.1. NF𝜅B Mediates the H/R-Induced Expression of COX-
2 in H9C2 Cardiomyocytes. The LDH release was higher
after H/R stimulation, suggesting the establishment of H/R-
induced injury model in cardiomyocytes (Figure 1(a)). The
expression ofCOX-2was significantly higherwhen compared
with control group (Figures 1(b) and 1(c)). The induction
of COX-2 was accompanied by the activation of NF𝜅B, as
evidenced by degradation of I𝜅B𝛼, and phosphorylation of
I𝜅B𝛼 and p65 in H/R-treated H9C2 cells (Figures 1(b) and
1(c)). NF𝜅B, when being activated, translocates to the nucleus
and initiates target genes transcription, including COX-2 in
different kinds of cells [29, 34, 35]. To test whether or not
the induction of COX-2 was mediated by NF𝜅B in cardiomy-
ocytes during H/R, the H9C2 cells were pretreated by the
selective NF𝜅B inhibitor, Helenalin. Despite the comparable
LDH leakage and expressions of I𝜅B𝛼 and phosphorylated
I𝜅B𝛼, the expression of phosphorylated p65 was significantly
lower in H/R + Helenalin group when compared with H/R
group, suggesting that Helenalin inhibited NF𝜅B activity
through the inhibition of p65 phosphorylation but not the
degradation of I𝜅B𝛼 (Figures 1(a), 1(b), and 1(c)). As antici-
pated, pretreatment with Helenalin significantly suppressed
COX-2 induction in H9C2 cells exposed to H/R (Figures
1(b) and 1(c)), suggesting that activated NF𝜅B mediated the
induction of COX-2 in H/R-treated H9C2 cardiomyocytes.
3.2. Inhibition of COX-2 Activity Attenuates H/R-Induced Cell
Injury. To observe whether or not the higher expression
of COX-2 contributed to H/R-induced cell injury in H9C2
cardiomyocytes, the cells were incubated with the COX-2
selective inhibitor, NS398, before being subjected to H/R.
Consistent with the higher COX-2 protein level in response
to H/R stimulation, the activity of COX-2 in the H/R group
was also significantly higher as compared to control cells,
and such augmentation in COX-2 activity was significantly
suppressed by NS398 (Figure 2(a)). This suggests that NS398
pretreatment was effective in inhibiting H/R-induced COX-2
activity.
LDH leakage is a biomarker of cell injury [36]. As shown
in Figure 2, the release of LDH to the culture medium
was significantly higher after H/R stimulation as compared
to control cells, whereas this LDH release was significantly
inhibited by pretreatment with NS398 when compared with
H/R group (Figure 2(b)). Consistently, cell viability was sig-
nificantly reduced after H/R stimulation, while pretreatment
with NS398 significantly enhanced the cell viability when
compared with H/R group (Figure 2(c)). Taken together,
these observations suggest that inhibition of COX-2 activity
significantly attenuated H/R-induced cell injury.
3.3. Inhibition of COX-2 Activity Alleviates H/R-Induced
Cell Apoptosis in H9C2 Cardiomyocytes. Apoptosis is the
hallmark of reperfusion injury in cardiomyocytes, leading
to late cell death [18, 19]. Thus, it is tempting to speculate
that pretreatment with NS398 may alleviate H/R-induced
cardiomyocytes apoptosis. To test this hypothesis, the levels
of apoptotic proteins, including Bax, Bcl2, total caspase-
3, and cleaved caspase-3, were determined. The expression
of Bax was not affected by H/R stimulation in the current
settings of cardiomyocyteH/Rmodel, whereas the expression
of Bcl2 was significantly decreased and the expression of
cleaved caspase-3 was drastically enhanced in the H/R group
as compared to control cells. Pretreatment with NS398
significantly reduced expression of cleaved caspase-3 and
enhanced Bcl2 expression (Figure 3(a)), resulting in signifi-
cant attenuation of H/R induced increases in apoptotic cell
death (Figure 3(b)) as measured by TUNEL assay which
detects theDNA fragmentation, a characteristic feature of cell
apoptosis [37]. Taken together, these data demonstrated that
inhibition of COX-2 alleviated H/R-induced cell apoptosis in
H9C2 cardiomyocytes.
3.4. COX-2 Mediates H/R-Induced Cell Injury and Apoptosis
in Primary Adult Rat Cardiomyocytes. The present study pri-
marily relied on work done on H9C2 cardiomyocytes to con-
solidate the effect of COX-2 on H/R-induced cell injury and
apoptosis; experiments were repeated on isolated primary
adult rat cardiomyocytes. Similar to that observed withH9C2
cardiomyocytes, H/R remarkably augmented the release of
LDHand the expression of cleaved caspase-3 and reduced cell
viability (Figure 4). Pretreatment with NS398 significantly
reduced LDH leakage (Figure 4(a)), improved cell viability
(Figure 4(b)), and alleviated expression of cleaved caspase-
3 (Figure 4(c)). Taken together, these data illustrated that
inhibition of COX-2 also attenuated H/R-induced cell injury
and apoptosis in primary rat cardiomyocytes.
3.5. Inhibition of COX-2 Activity Reduced H/R-Induced Proin-
flammatory Cytokines in H9C2 Cardiomyocytes. Inducible
COX-2 predominantly accounted for the formation of
prostanoids associated with inflammation [38]. Thus, the
present study investigated whether or not inhibition of COX-
2 affects the mRNA expression of H/R-induced proinflam-
matory cytokines in H9C2 cardiomyocytes. As shown in
Figure 5, H/R stimulation selectively induced the mRNA
expression of IL6 andTNF𝛼 but not IL1𝛽mRNA. Such higher
expression of IL6 andTNF𝛼was significantly suppressedwith
the NS398 pretreatment, suggesting that COX-2 may favor
proinflammatory environment in H/R-stimulated H9C2 car-
diomyocytes.
3.6. Inhibition of COX-2 Activity Reduced H/R-Induced Intra-
cellular ROS Level in H9C2 Cardiomyocytes. Generation of
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Figure 1: Activation of NF𝜅B mediates the H/R-induced expression of COX-2 in H9C2 cardiomyocytes. (a) The release of LDH (cell injury
marker) and (b) representative originalWestern blots of I𝜅B𝛼, phosphorylated I𝜅B𝛼 (S32/36), p65, phosphorylated p65 (S536), and COX-2 in
H9C2 cardiomyocytes with or without H/R stimulation (6 h hypoxia followed by 12 h reoxygenation) in the presence or absence of Helenalin
(NF𝜅B specific inhibitor, 10 𝜇M, 2 h). (c) Quantification of these proteins after normalization to 𝛽-actin. Data are shown as means ± SEM;
∗
𝑃 < 0.05 CTL versus H/R or H/R + Helenalin, #𝑃 < 0.05H/R versus H/R + Helenalin (one-way ANOVA followed by Tukey’s test in (a) and
nonparametric Mann–Whitney U test in (c)); 𝑛 = 4 per group.
reactive oxygen species (ROS) increases during myocardial
I/R and it plays a central role in the pathogenesis of
myocardial I/R injury [39]. Given that ROS are formed as
byproducts during the synthesis of prostanoids by COX [4],
hence the present study tested whether or not inhibition of
inducible COX-2 may block the H/R-induced intracellular
ROS production in H9C2 cardiomyocytes. As shown in
Figure 6, the ROS level was significantly higher in H/R
group when compared to control H9C2 cardiomyocytes.
However, such H/R-induced increase in ROS production was
significantly suppressed by NS398 pretreatment, suggesting
that inhibition of COX-2 activity may protect against H/R-
induced cell injury and apoptosis through attenuation of ROS
production.
3.7. Inhibition of COX-2 Activates Akt/iNOS/NO Signaling
Pathway in H9C2 Cardiomyocytes. The Akt signaling cas-
cade plays an important role in controlling cardiomyocytes
survival and apoptosis [40]. To investigate whether or not
NS398 pretreatment may affect the Akt pathway, H9C2
cardiomyocytes were subjected to H/R in the absence or
presence of NS398 and total Akt and phosphorylated Akt
protein (T450) expression was assessed. H/R significantly
reduced the expression of phosphorylated Akt, but not total
Akt level (Figure 7(a)). The level of phosphorylated Akt
in H/R-stimulated H9C2 cells was significantly higher by
NS398 pretreatment, suggesting that inhibition of COX-2
may activate Akt pathway and thus exert a cardioprotective
effect (Figure 7(a)). To confirm our speculation, LY294002,
the specific Akt inhibitor, was applied in the present study.
As anticipated, the NS398-induced augmentation of phos-
phorylated Akt was significantly suppressed by LY294002
pretreatment (Figure 7(a)). In addition, NS398 mediated
reduction of LDH leakage and cleaved caspase-3 level and
increase of cell viability was abolished in the presence of
LY294002 (Figures 7(a), 7(b), and 7(c)). This suggests that
activation of Akt mediated the cardioprotective effect of
NS398.
iNOS is the known downstream target of activated Akt
[41] and moderate increase of iNOS has been shown to
Oxidative Medicine and Cellular Longevity 7
CTL H/R H/R + NS398
0
50
100
150
#
CO
X-
2 
ac
tiv
ity
 (%
 o
f H
/R
 g
ro
up
)
∗
(a)
CTL H/R H/R + NS398
0
50
100
150
#
LD
H
 re
le
as
e (
%
 o
f c
on
tro
l)
∗
(b)
CTL H/R H/R + NS398
0
20
40
60
80
100
∗#
C
el
l v
ia
bi
lit
y 
(%
)
∗
(c)
Figure 2: Inhibition of COX-2 activity attenuates H/R-induced cell injury. (a)TheCOX-2 activity, (b) the release of LDH, and (c) cell viability
in H9C2 cardiomyocytes with or without H/R treatment in the presence or absence of NS398 (COX-2 specific inhibitor, 10𝜇M, 1 h). COX-2
activity was expressed against that in H/R group. The LDH leakage and cell viability were expressed against those in CTL group. Data are
shown as means ± SEM; ∗𝑃 < 0.05 CTL versus H/R or H/R + NS398, #𝑃 < 0.05 H/R versus H/R + NS398 (one-way ANOVA followed by
Tukey’s test); 𝑛 = 5 per group.
be cardioprotective during myocardial I/R injury through
the synthesis of NO [42]. It is feasible to hypothesize
that NS398 may protect against H/R-induced cell apopto-
sis through Akt/iNOS pathway in H9C2 cardiomyocytes.
Indeed, the expression of iNOS was significantly higher by
NS398 pretreatment as compared to H/R group (Figure 7(a)).
However, such NS398-mediated increase in iNOS expression
was blocked by LY294002, suggesting that iNOS worked
downstream of Akt in the current settings of cardiomy-
ocyte H/R (Figure 7(a)). To determine whether or not the
altered iNOS protein expression is related to intracellular
NO production, the NO level was compared among various
groups. As anticipated, pretreatment with NS398 resulted in
higher NO production as compared to H/R group, whereas
LY294002 significantly downregulated the NS398-mediated
increase in intracellular NO production (Figure 7(d)). To
further confirm whether or not iNOS was the primary
mediator through which NS398 mediated cardioprotective
effects, the iNOS-selective inhibitor 1400Wwas applied in the
present study. As expected, theNS398-induced augmentation
of iNOS expression was significantly suppressed in the
presence of 1400W (Figure 8(a)). In addition, the reduction
of cleaved caspase-3 level and LDH leakage and higher cell
viability in the H/R + NS398 group was almost diminished
in the presence of 1400W (Figures 8(a), 8(b), and 8(c)).
Furthermore, the NS398-mediated increase in intracellular
NO production was significantly downregulated by 1400W
pretreatment (Figure 8(d)). Taken together, these observa-
tions suggest that inhibition of COX-2 activity protected
against H/R-induced cell apoptosis through activation of
Akt/iNOS/NO pathway.
4. Discussion
COX-2 is expressed at very low level at physiological con-
dition but is strongly induced in response to different
stimuli, including proinflammatory cytokines, hypoxia, and
mechanical stress [9, 34, 43].The present study demonstrated
that COX-2 expression was significantly higher in H9C2
cardiomyocytes in response to H/R stimulation, which was
correspondent to severe posthypoxic cardiomyocyte injury.
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Figure 3: Inhibition of COX-2 activity alleviates H/R-induced cell apoptosis in H9C2 cardiomyocytes. (a) Representative original Western
blots of apoptosis related proteins (cleaved caspase-3, total caspase-3, Bcl2, and Bax) inH9C2 cardiomyocytes with orwithoutH/R stimulation
in the presence or absence of NS398. Protein presence of cleaved caspase-3 and Bcl2 was normalized to total caspase-3 and Bax, respectively.
(b) Representative fluorescence microscopy images of TUNEL staining. White triangle points to positive staining cells (green). DAPI (blue)
indicates the nucleus staining. Magnification ×200, scale bars: 100 𝜇m. TUNEL-positive cells% = TUNEL-positive cell numbers/total cell
numbers × 100%. Data are shown as means ± SEM; ∗𝑃 < 0.05 CTL versus H/R or H/R + NS398, #𝑃 < 0.05 H/R versus H/R + NS398
(nonparametric Mann–Whitney U test in (a) and one-way ANOVA followed by Tukey’s test in (b)); 𝑛 = 5 per group.
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Figure 4: Inhibition ofCOX-2 activity attenuatesH/R-induced cell injury and apoptosis in primary adult rat cardiomyocytes. (a)The release of
LDH and (b) cell viability in primary adult rat cardiomyocytes with or without H/R treatment (45min hypoxia followed by 2 h reoxygenation)
in the presence or absence of NS398.The LDH leakage and cell viability were expressed against those in CTL group. (c) Representative original
Western blots of cleaved caspase-3 and total caspase-3 in primary adult rat cardiomyocytes with or without H/R treatment in the presence or
absence of NS398. Quantification of cleaved caspase-3 was normalized to total caspase-3. Data are shown as means ± SEM; ∗𝑃 < 0.05 CTL
versus H/R, #𝑃 < 0.05H/R versus H/R + NS398 (one-way ANOVA followed by Tukey’s test in (a), (b) and nonparametric Mann–Whitney U
test in (c)); 𝑛 = 5 per group.
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Figure 5: Inhibition of COX-2 activity reducedH/R-induced proin-
flammatory cytokines expression in H9C2 cardiomyocytes. mRNA
expression of proinflammatory genes (IL1𝛽, IL6, and TNF𝛼) in
H9C2 cardiomyocytes subjected to H/R stimulation in the presence
or absence of NS398. mRNA levels are expressed against those
in H9C2 cardiomyocytes with no stimulation. Data are shown as
means± SEM; ∗𝑃 < 0.05CTLversusH/RorH/R+NS398, #𝑃 < 0.05
H/R versus H/R + NS398 (one-way ANOVA followed by Tukey’s
test); 𝑛 = 6 per group.
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Figure 6: Inhibition of COX-2 activity reduced H/R-induced intra-
cellular ROS level in H9C2 cardiomyocytes. ROS production was
detected in H9C2 cardiomyocytes with or without H/R stimulation
in the presence or absence of NS398 and it is expressed against that
in CTL group. Data are shown as means ± SEM; ∗𝑃 < 0.05 CTL
versus H/R or H/R + NS398, #𝑃 < 0.05 H/R versus H/R + NS398
(one-way ANOVA followed by Tukey’s test); 𝑛 = 6 per group.
This suggests that enhancement of COX-2 may be a mech-
anism of myocardial I/R injury. Our findings are in line
with several previous studies which showed that treatment
withCOX-2 selective inhibitor significantly improved cardiac
function and reduced myocardial infarction size in different
myocardial I/R animal models [12–15]. However, up to now,
no study has been conducted to address how inhibition of
COX-2 activity couples to multiple signaling molecules and
exerts cardioprotective effects. In the present study, COX-
2 inhibition with NS398 significantly enhanced cell viability
and attenuated H/R-induced LDH release, the expression of
cleaved caspase-3, and TUNEL-positive cell numbers in car-
diomyocytes (H9C2 cells and primary rat cardiomyocytes).
This demonstrated that inhibition of COX-2 activity atten-
uated H/R-induced cell injury and apoptosis. Furthermore,
NS398 pretreatment significantly inhibited proinflammatory
cytokine expressions (IL6 and TNF𝛼), reduced the formation
of ROS, and enhanced the activation of Akt/iNOS/NO signal-
ing pathway, which could represent themechanisms whereby
COX-2 inhibition attenuated H/R-induced cell apoptosis in
cardiomyocytes.
There are two main mechanisms, intrinsic and extrinsic
pathways, that induce the apoptotic cascade [44]. In the
intrinsic pathway, in response to stress signal, proapoptotic
proteins (such as Bax) disrupt the mitochondria mem-
brane integrity and cause mitochondrial dysfunction and the
release of Cytochrome C [44, 45], while the antiapoptotic
proteins (such as Bcl2, Bcl2-like protein 2) prevent cell apop-
tosis by interfering with proapoptotic member aggregation
[46, 47].The releasedCytochromeC forms a complex, named
apoptosome in the cytoplasm with ATP and Apaf-1, which
in turn activates caspase-9 and its downstream caspase-3,
the effector protein that initiates DNA fragmentation and
the degradation of cytoskeletal and nuclear proteins [48].
In the extrinsic pathway, upon ligand binding to death
receptors (such as TNF receptor) on the cell surface, the
death-inducing signaling complex is formed and activates
caspase-8 and caspase-10, which can cleave caspase-3 and
converge the extrinsic and intrinsic caspase cascades [16, 44].
Previous findings indicated that H/R stimulation induced
the cardiomyocytes apoptosis using both the intrinsic and
extrinsic pathways [16, 49, 50], whereas different duration
of H/R stimulation may initiate different apoptotic pathway
in cardiomyocytes. In the present study, H/R stimulation
should have induced cell apoptosis using both the intrinsic
and extrinsic ways, as evidenced by lower expression of
Bcl-2/Bax ratio and enhanced cleaved caspase-3 level and
TUNEL-positive cell numbers in the H/R group relative to
that in the control group H9C2 cardiomyocytes. Of note,
there was no change in the protein expression of Bax upon
H/R stimulation, which could be due to the specific H/R
condition (6 h hypoxia and 12 h reoxygenation) in the current
experiment setting. The fact that pretreatment with NS398
can significantly reduce the above-mentioned detrimental
effects of H/R stimulation and enhance posthypoxic H9C2
cardiomyocyte viability indicates that inhibition of COX-2
activity may protect against H/R-induced cell injury through
attenuation of cell apoptosis.
The next challenge was to examine how inhibition of
COX-2 protects against H/R-induced cell apoptosis. During
myocardial I/R injury, sustained proinflammatory environ-
ment (infiltration of inflammatory cells, release of proin-
flammatory cytokines and chemokines) favors the cardiomy-
ocytes apoptosis, leading to the loss of cardiomyocyte volume
and the subsequent cardiac dysfunction [51]. Given the fact
that prostaglandins—by the action of COX—play a key
role in the generation of the inflammatory response [38],
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Figure 7: Inhibition of COX-2 activity protects against H/R-induced cell apoptosis via Akt-dependent enhancement of iNOS expression.
(a) Representative original Western blots of total Akt, phosphorylated Akt (T450), iNOS, cleaved caspase-3, and total caspase-3 in H9C2
cardiomyocytes with or without H/R stimulation in the presence or absence of NS398 or LY294002 (Akt-specific inhibitor, 10𝜇M, 1 h).
Phosphorylated Akt, iNOS, and cleaved caspase-3 were normalized to total Akt, GAPDH, and total caspase-3, respectively. (b) The release
of LDH, (c) cell viability, and (d) NO content were determined in H9C2 cardiomyocytes with or without H/R stimulation in the presence
or absence of NS398 or LY294002 and were expressed against those in CTL group. Data are shown as means ± SEM; ∗𝑃 < 0.05 CTL versus
H/R or H/R + NS398 or H/R + NS398 + LY294002, #𝑃 < 0.05H/R versus H/R + NS398, and Δ𝑃 < 0.05H/R + NS398 versus H/R + NS398 +
LY294002 (nonparametric Mann–Whitney U test in (a) and one-way ANOVA followed by Tukey’s test in (b), (c), and (d)); 𝑛 = 5 per group.
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Figure 8: iNOS primarily mediated cardioprotective effects of NS398 in H/R-induced H9C2 cardiomyocytes apoptosis. (a) Representative
original Western blots of iNOS, cleaved caspase-3, total caspase-3, and GAPDH in H9C2 cardiomyocytes with or without H/R stimulation in
the presence or absence of NS398 or 1400W (iNOS specific inhibitor, 1 𝜇M, 30min). iNOS and cleaved caspase-3 were normalized to GAPDH
and total caspase-3, respectively. (b)The release of LDH, (c) cell viability, and (d) NO content were determined in H9C2 cardiomyocytes with
or without H/R stimulation in the presence or absence of NS398 or 1400W and were expressed against those in CTL group. Data are shown
as means ± SEM; ∗𝑃 < 0.05 CTL versus H/R or H/R + NS398 or H/R + NS398 + 1400W, #𝑃 < 0.05 H/R versus H/R + NS398, and Δ𝑃 < 0.05
H/R + NS398 versus H/R + NS398 + 1400W (nonparametric Mann–Whitney U test in (a) and one-way ANOVA followed by Tukey’s test in
(b), (c), and (d)); 𝑛 = 5 per group.
inhibition of COX-2 activity may attenuate H/R-induced
cell apoptosis through blocking the expression of proinflam-
matory cytokines. Indeed, pretreatment with NS398 signif-
icantly reduced H/R-induced mRNA expression of IL6 and
TNF𝛼, both of which have been well established to possess
proapoptotic effects [52, 53]. In particular, through binding
with TNF receptor on the cell surface, TNF𝛼 can initiate
extrinsic apoptotic pathway and favor the formation of death-
inducing signaling complex, leading to cell apoptosis [54].
Thus, lower TNF𝛼 level may serve as a mechanism whereby
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NS398 reduces posthypoxic H9C2 cell apoptosis. However,
how does inhibition of COX-2 activity downregulate TNF𝛼
level and whether TNF𝛼-mediated extrinsic apoptosis is
affected by NS398 pretreatment are still unclear and warrant
further investigation.
Nitric oxide (NO) represents one of the most important
defense mechanisms against cell apoptosis, which can either
indirectly prevent the caspase-3-like protease activation in
cGMP-dependent way or directly inhibit the activation
of caspase-3-like protease through S-nitrosylation of the
enzyme [55]. Thus, the concomitance of higher intracellular
NO level and lower posthypoxic apoptosis in NS398 pre-
treated cells suggests that inhibition of COX-2 may protect
against H/R-induced cell apoptosis through augmentation
of NO production. Indeed, the present study proposed two
distinct ways to identify how inhibition of COX-2 affects
intracellular NO level. (1) ROS/NO balance: ROS are gen-
erated intracellularly through multiple metabolic activities.
The metabolism of arachidonic acid into specific prostanoids
relies on the activity of COX, duringwhichROS are formed as
by-products [5, 56].Theoverproduction of ROSwas observed
in myocardial I/R injury and promoted the development of
this ischemic disease [39]. Indeed, in the current study, higher
intracellular ROS level was concomitant with induction of
COX-2 in H/R-stimulated H9C2 cardiomyocytes, whereas
inhibition of COX-2 activity significantly alleviated ROS
generation. Of note, elevated formation of ROS closely linked
to lowNObioavailability, since excessive ROS production not
only disturbs the equilibrium of NOS and NO, but also reacts
with NO [which is unstable in oxygenated environment]
to form nitrite salt (i.e., peroxynitrite), which exacerbates
proapoptotic events [57, 58]. Indeed, previous studies from
our group reported that treatment with antioxidants N-
Acetylcysteine and allopurinol in the myocardial I/R rat
model significantly reduced myocardial ROS formation, pro-
duced higher NO content in cardiac tissue, and alleviated
infarct size [59, 60]. Taken together, these multiple lines
of evidence suggest that inhibition of COX-2 may have
protected cell apoptosis through attenuation of ROS gen-
eration. (2) Akt/iNOS/NO signaling pathway: activation of
Akt promotes the mRNA and protein expression of COX-
2 in human endometrial cancer cells [21]. However, in the
present study, induction of COX-2 in H/R-stimulated H9C2
cardiomyocytes was accompanied by lower phosphorylation
of Akt. In addition, inhibition of COX-2 in H/R-stimulated
cells promotes activation of Akt, suggesting that Akt/COX-
2 cascade may be stimuli-and cell-specific. It has become
evident that activation of PI3K/Akt signaling pathway may
protect against cardiomyocytes apoptosis through facilitating
the NO production during ischemic disease [40].The forma-
tion of NO is catalyzed by nitric oxide synthase, including
neuronal NOS, endothelial NOS, and iNOS [58]. Although
several reports suggested a role of iNOSmediated production
of NO in cardiac damage [61, 62], there are accumulating
evidences showing that iNOS exerts cardioprotective effects
in acute and chronic heart disease [63–65]. Indeed, in
the present study, higher expression of phosphorylated Akt
was concomitant with enhanced expression of iNOS and
intracellular NO production in NS398 pretreated H9C2
cardiomyocytes, whereas LY294002 (Akt kinase specific
inhibitor) or 1400W (iNOS specific inhibitor) cancelled
NS398-mediated cardioprotective effects. Of note, 1400W
treatment was associated with lower iNOS protein expression
as compared to H/R group. Although the underlying mech-
anism is still unclear, it could be possible that 1400W may
interrupt the transcriptional control of themRNA expression
of iNOS via inhibition of inflammatory stress [66, 67].
Taken together, these observations suggested that inhibition
of COX-2 may protect cell apoptosis through activation of
Akt/iNOS/NO signaling pathway.
Findings of the current study suggest that NF𝜅B is a
major player/mediator in H/R-induced expression of COX-2
in H9C2 cardiomyocytes. However, besides the NF𝜅B/COX-
2 signaling, NF𝜅B also controls hundreds of gene expressions
which are involved in inflammation, cell growth, differentia-
tion, and cell apoptosis [68]. In particular, accumulating evi-
dences have demonstrated that NF𝜅B promotes cell survival
due to the upregulation of antiapoptotic genes, including
A1/Bfl1 [69], Bcl-XL [70], and Nr13 [71].Thus, transcriptional
factor NF𝜅B exerts both pro- and antiapoptotic effects in
the context of apoptotic stimulus [72]. In the present study,
when Helenalin was applied to block NF𝜅B activity, COX-
2 was sequentially blocked, but other downstream signals of
NF𝜅B (likeNF𝜅B-mediated anti-apoptotic genes)may also be
suppressed, and this could be the reason why Helenalin did
not block LDH release as NS398 did.
In the clinical settings, higher incidence of myocardial
infarction has been reported in individuals who chronically
take Vioxx and Celebrex, specific inhibitors of COX-2 [73,
74]; thus these selective inhibitors of COX-2 are not recom-
mended for long-term use for patients. However, consistent
with the work done in experimental animal models [12–15],
the present study demonstrated that COX-2 was strongly
induced by NF𝜅B activation in response to H/R stimula-
tion. Acute pretreatment with NS398, the COX-2 specific
inhibitor, can protect against H/R-induced cell injury and
apoptosis through attenuation of proinflammatory cytokines
expression, reduction of ROS formation, and activation of
Akt/iNOS/NO signaling pathway in cardiomyocytes (Fig-
ure 9).
5. Conclusion
From a practical standpoint, further understanding on how
COX-2 impacts cardiomyocytes apoptosis may have pro-
found clinical implications in the light of the significant role
of apoptosis in ischemic heart disease and the widespread
use of COX-2 selective inhibitors. In conclusion, findings
from the current study provide evidence to suggest that
activation of NF𝜅B during cardiomyocyte H/R induces the
expression of COX-2 and that higher COX-2 expression
duringH/R exacerbates cardiomyocyte H/R injury viamech-
anisms that involve cross talk among inflammation, ROS, and
Akt/iNOS/NO signaling.
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Figure 9: Schematic of proposed signaling involved in the effect of COX-2 in H/R-induced cardiomyocytes apoptosis. In cardiomyocytes,
COX-2 was strongly induced in response to H/R stimulation in NF𝜅B-dependent way. Acute pretreatment with NS398, the COX-2 specific
inhibitor, can protect against H/R-induced cell injury and apoptosis through attenuation of proinflammatory cytokines expression, ROS
formation, and activation of Akt/iNOS/NO signaling pathway.
Acknowledgments
The authors’ research was supported by General Research
Fund (17123915M, 17124614M, and 17121315M, Research
Grants Council of Hong Kong), Educational Commission of
Jilin Province of China (2016-471), and Youth Foundation of
The First Hospital of Jilin University.
References
[1] A. E. Moran, M. H. Forouzanfar, G. A. Roth et al., “The global
burden of ischemic heart disease in 1990 and 2010: the Global
Burden of Disease 2010 study,” Circulation, vol. 129, no. 14, pp.
1493–1501, 2014.
[2] D. J. Hausenloy and D. M. Yellon, “Myocardial ischemia-
reperfusion injury: a neglected therapeutic target,” The Journal
of Clinical Investigation, vol. 123, no. 1, pp. 92–100, 2013.
[3] Z. Xia, Y. Chen, Q. Fan, and M. Xue, “Oxidative stress-
mediated reperfusion injury:mechanism and therapies,”Oxida-
tive Medicine and Cellular Longevity, vol. 2014, Article ID
373081, 2 pages, 2014.
[4] L. J. Marnett, S. W. Rowlinson, D. C. Goodwin, A. S. Kalgutkar,
and C. A. Lanzo, “Arachidonic acid oxygenation by COX-1 and
COX-2. Mechanisms of catalysis and inhibition,”The Journal of
Biological Chemistry, vol. 274, no. 33, pp. 22903–22906, 1999.
[5] M. S.-K. Wong and P. M. Vanhoutte, “COX-mediated en-
dothelium-dependent contractions: from the past to recent
discoveries,”Acta Pharmacologica Sinica, vol. 31, no. 9, pp. 1095–
1102, 2010.
[6] L. Pang, Y. Cai, E. H. Tang, M. G. Irwin, H. Ma, and Z. Xia,
“Prostaglandin E receptor subtype 4 signaling in the heart:
role in ischemia/reperfusion injury and cardiac hypertrophy,”
Journal of Diabetes Research, vol. 2016, Article ID 1324347, 10
pages, 2016.
[7] C. A. Rouzer and L. J. Marnett, “Cyclooxygenases: structural
and functional insights,” The Journal of Lipid Research, vol. 50,
supplement, pp. S29–S34, 2009.
[8] K. Schro¨r, K. C. Zimmermann, and R. Tannha¨user, “Augmented
myocardial ischaemia by nicotine—mechanisms and their pos-
sible significance,” British Journal of Pharmacology, vol. 125, no.
1, pp. 79–86, 1998.
[9] S. C. Y. Wong, M. Fukuchi, P. Melnyk, I. Rodger, and A.
Giaid, “Induction of cyclooxygenase-2 and activation of nuclear
factor-𝜅B in myocardium of patients with congestive heart
failure,” Circulation, vol. 98, no. 2, pp. 100–103, 1998.
[10] K. Shinmura, Y.-T. Xuan, X.-L. Tang et al., “Inducible nitric
oxide synthase modulates cyclooxygenase-2 activity in the
heart of conscious rabbits during the late phase of ischemic
preconditioning,” Circulation Research, vol. 90, no. 5, pp. 602–
608, 2002.
Oxidative Medicine and Cellular Longevity 15
[11] G. Rossoni, M. N. Muscara, G. Cirino, and J. L. Wallace, “Inhi-
bition of cyclo-oxygenase-2 exacerbates ischaemia-induced
acute myocardial dysfunction in the rabbit,” British Journal of
Pharmacology, vol. 135, no. 6, pp. 1540–1546, 2002.
[12] L. Lada-Moldovan, S. Kaloustian, T.M. Bah, S.-A. Girard,M.-A.
De´ry, and G. Rousseau, “Chronic pretreatment with celecoxib
reduces infarct size,” Journal of Cardiovascular Pharmacology,
vol. 54, no. 1, pp. 31–37, 2009.
[13] T. Saito, I.W. Rodger, H. Shennib, F. Hu, L. Tayara, andA. Giaid,
“Cyclooxygenase-2 (COX-2) in acute myocardial infarction:
cellular expression and use of selective COX-2 inhibitor,”
Canadian Journal of Physiology and Pharmacology, vol. 81, no.
2, pp. 114–119, 2003.
[14] S. A. Saeed and S. Ahmed, “Role of cyclooxygenase-2 in
myocardial infarction and ischaemia,” Journal of the College of
Physicians and Surgeons Pakistan, vol. 16, no. 5, pp. 324–328,
2006.
[15] A. Carnieto Jr., P. M. M. Dourado, P. L. D. Luz, and A. C. P.
Chagas, “Selective cyclooxygenase-2 inhibition protects against
myocardial damage in experimental acute ischemia,” Clinics,
vol. 64, no. 3, pp. 245–252, 2009.
[16] C. S. Kunak, O. Kukula, E. Mutlu et al., “The effect of etori-
coxib on hepatic ischemia-reperfusion injury in rats,”Oxidative
Medicine and Cellular Longevity, vol. 2015, Article ID 598162, 8
pages, 2015.
[17] J. D. McCully, H. Wakiyama, Y.-J. Hsieh, M. Jones, and S.
Levitsky, “Differential contribution of necrosis and apoptosis in
myocardial ischemia-reperfusion injury,” American Journal of
Physiology—Heart and Circulatory Physiology, vol. 286, no. 5,
pp. H1923–H1935, 2004.
[18] R. A. Gottlieb, K. O. Burleson, R. A. Kloner, B. M. Babior, and
R. L. Engler, “Reperfusion injury induces apoptosis in rabbit
cardiomyocytes,” The Journal of Clinical Investigation, vol. 94,
no. 4, pp. 1621–1628, 1994.
[19] R. Badalzadeh, B. Mokhtari, and R. Yavari, “Contribution
of apoptosis in myocardial reperfusion injury and loss of
cardioprotection in diabetes mellitus,” Journal of Physiological
Sciences, vol. 65, no. 3, pp. 201–215, 2015.
[20] A. Abbate, D. Santini, G. G. L. Biondi-Zoccai et al., “Cyclo-
oxygenase-2 (COX-2) expression at the site of recent myocar-
dial infarction: friend or foe?”Heart, vol. 90, no. 4, pp. 440–443,
2004.
[21] M.-E. St-Germain, V. Gagnon, I. Mathieu, S. Parent, and E.
Asselin, “Akt regulates COX-2mRNA and protein expression in
mutated-PTEN human endometrial cancer cells,” International
journal of oncology, vol. 24, no. 5, pp. 1311–1324, 2004.
[22] S. Lei, H. Li, J. Xu et al., “Hyperglycemia-induced protein
kinase C 𝛽
2
activation induces diastolic cardiac dysfunction in
diabetic rats by impairing caveolin-3 expression and Akt/eNOS
signaling,” Diabetes, vol. 62, no. 7, pp. 2318–2328, 2013.
[23] S. Lei, W. Su, H. Liu et al., “Nitroglycerine-induced nitrate
tolerance compromises propofol protection of the endothelial
cells against TNF-𝛼: the role of PKC-𝛽
2
and nadph oxidase,”
Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID
678484, 9 pages, 2013.
[24] H. Li, W. Yao, M. G. Irwin et al., “Adiponectin ameliorates
hyperglycemia-induced cardiac hypertrophy and dysfunction
by concomitantly activatingNrf2 andBrg1,” Free Radical Biology
and Medicine, vol. 84, pp. 311–321, 2015.
[25] G. Lyß, A. Knorre, T. J. Schmidt, H. L. Pahl, and I. Merfort, “The
anti-inflammatory sesquiterpene lactone helenalin inhibits the
transcription factor NF-𝜅B by directly targeting p65,” The
Journal of Biological Chemistry, vol. 273, no. 50, pp. 33508–
33516, 1998.
[26] R. Schuligoi, R. Amann, C. Prenn, and B. A. Peskar, “Effects
of the cyclooxygenase-2 inhibitor NS-398 on thromboxane
and leukotriene synthesis in rat peritoneal cells,” Inflammation
Research, vol. 47, no. 5, pp. 227–230, 1998.
[27] S. Qiao, X. Mao, Y. Wang et al., “Remifentanil preconditioning
reduces postischemic myocardial infarction and improves left
ventricular performance via activation of the Janus activated
kinase-2/signal transducers and activators of transcription-3
signal pathway and subsequent inhibition of glycogen synthase
kinase-3𝛽 in rats,”Critical CareMedicine, vol. 44, no. 3, pp. e131–
e145, 2016.
[28] R. Xue, S. Lei, Z.-Y. Xia et al., “Selective inhibition of
PTEN preserves ischaemic post-conditioning cardioprotection
in STZ-induced Type 1 diabetic rats: role of the PI3K/Akt and
JAK2/STAT3 pathways,”Clinical Science, vol. 130, no. 5, pp. 377–
392, 2016.
[29] Y. Cai, G. K. Sukhova, H. K.Wong et al., “Rap1 induces cytokine
production in pro-inflammatory macrophages through NF𝜅B
signaling and is highly expressed in human atherosclerotic
lesions,” Cell Cycle, vol. 14, no. 22, pp. 3580–3592, 2015.
[30] Y. Cai, F. Ying, E. Song et al., “Mice lacking prostaglandin
E receptor subtype 4 manifest disrupted lipid metabolism
attributable to impaired triglyceride clearance,” The FASEB
Journal, vol. 29, no. 12, pp. 4924–4936, 2015.
[31] Y. Liu, J. Jin, S. Qiao et al., “Inhibition of PKC𝛽2 overexpres-
sion ameliorates myocardial ischaemia/reperfusion injury in
diabetic rats via restoring caveolin-3/Akt signaling,” Clinical
Science, vol. 129, no. 4, pp. 331–344, 2015.
[32] B. Liu, G. Wang, J. Yang, X. Pan, Z. Yang, and L. Zang,
“Berberine inhibits human hepatoma cell invasion without
cytotoxicity in healthy hepatocytes,” PLoS ONE, vol. 6, no. 6,
Article ID e21416, 2011.
[33] M. Stæhr, K. Madsen, P. M. Vanhoutte, P. B. Hansen, and B.
L. Jensen, “Disruption of COX-2 and eNOS does not confer
protection from cardiovascular failure in lipopolysaccharide-
treated conscious mice and isolated vascular rings,” American
Journal of Physiology—Regulatory Integrative and Comparative
Physiology, vol. 301, no. 2, pp. R412–R420, 2011.
[34] L. J. Crofford, B. Tan, C. J. McCarthy, and T. Hla, “Involvement
of nuclear factor 𝜅B in the regulation of cyclooxygenase-
2 expression by interleukin-1 in rheumatoid synoviocytes,”
Arthritis & Rheumatism, vol. 40, no. 2, pp. 226–236, 1997.
[35] K.-M. Lee, B.-S. Kang, H.-L. Lee et al., “Spinal NF-kB activation
induces COX-2 upregulation and contributes to inflammatory
pain hypersensitivity,” European Journal of Neuroscience, vol. 19,
no. 12, pp. 3375–3381, 2004.
[36] C. Legrand, J. M. Bour, C. Jacob et al., “Lactate dehydrogenase
(LDH) activity of the cultured eukaryotic cells as marker of the
number of dead cells in the medium [corrected],” Journal of
Biotechnology, vol. 25, no. 3, pp. 231–243, 1992.
[37] A. Saraste, “Morphologic criteria and detection of apoptosis,”
Herz, vol. 24, no. 3, pp. 189–195, 1999.
[38] E. Ricciotti and G. A. Fitzgerald, “Prostaglandins and inflam-
mation,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol.
31, no. 5, pp. 986–1000, 2011.
[39] V. Braunersreuther and V. Jaquet, “Reactive oxygen species
in myocardial reperfusion injury: from physiopathology to
therapeutic approaches,”Current Pharmaceutical Biotechnology,
vol. 13, no. 1, pp. 97–114, 2012.
16 Oxidative Medicine and Cellular Longevity
[40] T. Matsui, J. Tao, F. Del Monte et al., “Akt activation preserves
cardiac function and prevents injury after transient cardiac
ischemia in vivo,” Circulation, vol. 104, no. 3, pp. 330–335, 2001.
[41] J. H. Oh, T.-J. Lee, J.-W. Park, and T. K. Kwon, “Withaferin A
inhibits iNOS expression and nitric oxide production by Akt
inactivation and down-regulating LPS-induced activity of NF-
𝜅B in RAW 264.7 cells,” European Journal of Pharmacology, vol.
599, no. 1–3, pp. 11–17, 2008.
[42] R. Bolli, “Cardioprotective function of inducible nitric oxide
synthase and role of nitric oxide in myocardial ischemia and
preconditioning: an overview of a decade of research,” Journal
of Molecular and Cellular Cardiology, vol. 33, no. 11, pp. 1897–
1918, 2001.
[43] M. Joldersma, E.H. Burger, C.M. Semeins, and J. Klein-Nulend,
“Mechanical stress induces COX-2 mRNA expression in bone
cells from elderly women,” Journal of Biomechanics, vol. 33, no.
1, pp. 53–61, 2000.
[44] S. Elmore, “Apoptosis: a review of programmed cell death,”
Toxicologic Pathology, vol. 35, no. 4, pp. 495–516, 2007.
[45] D. J. Granville, J. R. Shaw, S. Leong et al., “Release of cytochrome
c, Bax migration, bid cleavage, and activation of caspases 2, 3,
6, 7, 8, and 9 during endothelial cell apoptosis,” The American
Journal of Pathology, vol. 155, no. 4, pp. 1021–1025, 1999.
[46] A. Burlacu, “Regulation of apoptosis by Bcl-2 family proteins,”
Journal of Cellular andMolecularMedicine, vol. 7, no. 3, pp. 249–
257, 2003.
[47] J. Zhang, Y. Xia, Z. Xu, and X. Deng, “Propofol suppressed
hypoxia/reoxygenation-induced apoptosis in HBVSMC by reg-
ulation of the expression of Bcl-2, Bax, Caspase3, Kir6.1, and
p-JNK,” Oxidative Medicine and Cellular Longevity, vol. 2016,
Article ID 1518738, 11 pages, 2016.
[48] A. G. Porter and R. U. Ja¨nicke, “Emerging roles of caspase-3 in
apoptosis,” Cell Death and Differentiation, vol. 6, no. 2, pp. 99–
104, 1999.
[49] G. Chang, D. Zhang, J. Liu et al., “Exenatide protects against
hypoxia/reoxygenation-induced apoptosis by improving mito-
chondrial function in H9c2 cells,” Experimental Biology and
Medicine, vol. 239, no. 4, pp. 414–422, 2014.
[50] K. Li, Y.-C. Cui, H. Zhang et al., “Glutamine reduces the apop-
tosis of H9C2 cells treated with high-glucose and reperfusion
through an oxidation-related mechanism,” PLoS ONE, vol. 10,
no. 7, Article ID e0132402, 2015.
[51] N. G. Frangogiannis, “Targeting the inflammatory response in
healing myocardial infarcts,” Current Medicinal Chemistry, vol.
13, no. 16, pp. 1877–1893, 2006.
[52] Y. P.Moodley, N. L. A.Misso, A. K. Scaffidi et al., “Inverse effects
of interleukin-6 on apoptosis of fibroblasts from pulmonary
fibrosis and normal lungs,”American Journal of Respiratory Cell
and Molecular Biology, vol. 29, no. 4, pp. 490–498, 2003.
[53] S. B. Haudek, G. E. Taffet, M. D. Schneider, and D. L. Mann,
“TNF provokes cardiomyocyte apoptosis and cardiac remod-
eling through activation of multiple cell death pathways,” The
Journal of Clinical Investigation, vol. 117, no. 9, pp. 2692–2701,
2007.
[54] Y. Wang, A. Shnyra, C. Africa, C. Warholic, and C. McArthur,
“Activation of the extrinsic apoptotic pathway by TNF-𝛼
in Human Salivary Gland (HSG) cells in vitro, suggests a
role for the TNF receptor (TNF-R) and Intercellular Adhe-
sion Molecule-1 (ICAM-1) in Sjo¨gren’s Syndrome-associated
autoimmune sialadenitis,” Archives of Oral Biology, vol. 54, no.
11, pp. 986–996, 2009.
[55] Y.-M.Kim, R. V. Talanian, andT. R. Billiar, “Nitric oxide inhibits
apoptosis by preventing increases in caspase-3-like activity via
two distinct mechanisms,” The Journal of Biological Chemistry,
vol. 272, no. 49, pp. 31138–31148, 1997.
[56] P. M. Vanhoutte, H. Shimokawa, M. Feletou, and E. Tang,
“Endothelial dysfunction and vascular disease—a thirthieth
anniversary update,” Acta Physiologica, 2016.
[57] Y. Zhao, P. M. Vanhoutte, and S. W. S. Leung, “Vascular nitric
oxide: beyond eNOS,” Journal of Pharmacological Sciences, vol.
129, no. 2, pp. 83–94, 2015.
[58] Y. Liu, Q. Qin, A. Bo, and etal, “The effect of sodium nitrite
on induction of apoptosis in human gastric adenocarcinoma
epithelia (AGS) cells,” Pharmacology & Pharmacy, vol. 6, no. 11,
pp. 496–501, 2015.
[59] X.Mao, T.Wang, Y. Liu et al., “N-acetylcysteine and allopurinol
confer synergy in attenuating myocardial ischemia injury via
restoring HIF-1𝛼/HO-1 signaling in diabetic rats,” PLoS ONE,
vol. 8, no. 7, Article ID e68949, 2013.
[60] T. Wang, X. Mao, H. Li et al., “N-Acetylcysteine and allopuri-
nol up-regulated the Jak/STAT3 and PI3K/Akt pathways via
adiponectin and attenuated myocardial postischemic injury in
diabetes,” Free Radical Biology and Medicine, vol. 63, pp. 291–
303, 2013.
[61] A.M. Shah, “Inducible nitric oxide synthase and cardiovascular
disease,” Cardiovascular Research, vol. 45, no. 1, pp. 148–155,
2000.
[62] I. N. Mungrue, R. Gros, X. You et al., “Cardiomyocyte overex-
pression of iNOS in mice results in peroxynitrite generation,
heart block, and sudden death,” The Journal of Clinical Inves-
tigation, vol. 109, no. 6, pp. 735–743, 2002.
[63] A. A. Bulhak, P.-O. Sjo¨quist, C.-B. Xu, L. Edvinsson, and J.
Pernow, “Protection against myocardial ischaemia/reperfusion
injury by PPAR-𝛼 activation is related to production of nitric
oxide and endothelin-1,” Basic Research in Cardiology, vol. 101,
no. 3, pp. 244–252, 2006.
[64] D. V. Cuong, N. Kim, B. Y. Jae et al., “Nitric oxide-cGMP-
protein kinase G signaling pathway induces anoxic precondi-
tioning through activation of ATP-sensitive K+ channels in rat
hearts,” American Journal of Physiology—Heart and Circulatory
Physiology, vol. 290, no. 5, pp. H1808–H1817, 2006.
[65] X.-Q. Tang, H.-M. Yu, J.-L. Zhi et al., “Inducible nitric oxide
synthase and cyclooxgenase-2 mediate protection of hydrogen
peroxide preconditioning against apoptosis induced by oxida-
tive stress in PC12 cells,” Life Sciences, vol. 79, no. 9, pp. 870–876,
2006.
[66] P. Patel, W.-N. Qi, D. M. Allen et al., “Inhibition of iNOS with
1400W improves contractile function and alters NOS gene and
protein expression in reperfused skeletal muscle,”Microsurgery,
vol. 24, no. 4, pp. 324–331, 2004.
[67] Q. Tang, C. I. Svensson, B. Fitzsimmons, M. Webb, T. L.
Yaksh, and X.-Y. Hua, “Inhibition of spinal constitutive NOS-
2 by 1400W attenuates tissue injury and inflammation-induced
hyperalgesia and spinal p38 activation,” European Journal of
Neuroscience, vol. 25, no. 10, pp. 2964–2972, 2007.
[68] H. L. Pahl, “Activators and target genes of Rel/NF-𝜅B transcrip-
tion factors,” Oncogene, vol. 18, no. 49, pp. 6853–6866, 1999.
[69] R. J. Grumont, I. J. Rourke, and S. Gerondakis, “Rel-dependent
induction of A1 transcription is required to protect B cells
from antigen receptor ligation-induced apoptosis,” Genes &
Development, vol. 13, no. 4, pp. 400–411, 1999.
[70] H. H. Lee, H. Dadgostar, Q. Cheng, J. Shu, and G. Cheng, “NF-
𝜅B-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for
Oxidative Medicine and Cellular Longevity 17
CD40 survival signaling in B lymphocytes,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 96, no. 16, pp. 9136–9141, 1999.
[71] M. Barkett and T. D. Gilmore, “Control of apoptosis by Rel/NF-
𝜅B transcription factors,” Oncogene, vol. 18, no. 49, pp. 6910–
6924, 1999.
[72] B. Kaltschmidt, C. Kaltschmidt, T. G.Hofmann, S. P. Hehner,W.
Dro¨ge, andM. L. Schmitz, “The pro- or anti-apoptotic function
of NF-𝜅B is determined by the nature of the apoptotic stimulus,”
European Journal of Biochemistry, vol. 267, no. 12, pp. 3828–3835,
2000.
[73] E. Fosslien, “Cardiovascular complications of non-steroidal
anti-inflammatory drugs,” Annals of Clinical and Laboratory
Science, vol. 35, no. 4, pp. 347–385, 2005.
[74] S. Fries and T. Grosser, “The cardiovascular pharmacology of
COX-2 inhibition,” Hematology/The Education Program of the
American Society of Hematology, vol. 2005, no. 1, pp. 445–451,
2005.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
